Component
Omoringone and other isolated Moringa leaf CYP3A4 inhibitors
Species, preparation, dose and limitations are retained on linked claims.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
Several isolated Moringa leaf metabolites inhibited CYP3A4 at 41.5-100 micromolar but showed no remarkable CYP2D6 inhibition in the same in-vitro panel.
Experimental context and source evidence
- dose
- Isolated constituents up to the assay range
- duration
- Acute
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Recombinant or assay-system human CYP3A4/CYP2D6 panel
- limitations
- Bioavailability was unresolved, so these concentrations cannot be treated as expected human exposure or used to predict a specific medicine interaction.
- nutrient_topic
- Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
- organism
- Recombinant or assay-system human CYP3A4/CYP2D6 panel
- plain_language
- Several isolated Moringa leaf metabolites inhibited CYP3A4 at 41.5-100 micromolar but showed no remarkable CYP2D6 inhibition in the same in-vitro panel.
- primary_references
- Isolation, synthesis, and drug interaction potential of secondary metabolites derived from the leaves of miracle tree (Moringa oleifera) against CYP3A4 and CYP2D6 isozymes. (2019). https://pubmed.ncbi.nlm.nih.gov/31301970/ DOI: 10.1016/j.phymed.2019.153010
- route
- In vitro
- tissue
- CYP isozyme inhibition
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 211–220
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Recombinant or assay-system human CYP3A4/CYP2D6 panel · source_derived_draft · unverified_draft
## moringa-isolated-constituent-cyp-selectivity Several isolated Moringa leaf metabolites inhibited CYP3A4 at 41.5-100 micromolar but showed no remarkable CYP2D6 inhibition in the same in-vitro panel. Model/species: Recombinant or assay-system human CYP3A4/CYP2D6 panel Tissue/system: CYP isozyme inhibition Exposure: Isolated constituents up to the assay range Route: In vitro Duration: Acute Limits: Bioavailability was unresolved, so these concentrations cannot be treated as expected human exposure or used to predict a specific medicine interaction. Primary reference: Isolation, synthesis, and drug interaction potential of secondary metabolites derived from the leaves of miracle tree (Moringa oleifera) against CYP3A4 and CYP2D6 isozymes. (2019). https://pubmed.ncbi.nlm.nih.gov/31301970/ DOI: 10.1016/j.phymed.2019.153010 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.